Project Updates

Applied Pharmaceutical Innovation

Credit: START Architecture and CRB Consulting Engineers

Location: Alberta, Canada
Project type: Critical medicines production facility
Initial investment: C$5.6m
​​​​​​​Expected opening: 2026

Applied Pharmaceutical Innovation (API) will build a pharmaceutical manufacturing facility named the Critical Medicines Production Centre (CMPC) in Canada in collaboration with the University of Alberta’s Li Ka Shing Applied Virology Institute.

Pharmascience

Credit: CNW Group / Pharmascience

Location: Quebec, Canada 
Project type: manufacturing facility expansion
Estimated investment: $120m 
​​​​​​​Expected completion: End of 2026

Pharmascience, a pharmaceutical company based in Canada, is undertaking an expansion of its sterile injectables manufacturing facility located at its existing Candiac campus, near the St.Lawrence River in Quebec, Canada.

Simtra BioPharma Solutions

Credit: Paul Reverve / Shutterstock.com

Location: Indiana, US 
Project type: Manufacturing site expansion 
Estimated investment: $250m 
Expected completion: 2025

Simtra BioPharma Solutions (Simtra) will expand its manufacturing campus in Bloomington, Indiana, US, with an aseptic manufacturing and filing facility.

Go to article: Home | Enhancing therapy adherence with prodrugsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: CytivaGo to article: NiproGo to article: Laboratorios Argenol Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Avenga Company InsightGo to article: Lactalis IngredientsGo to article: BSP PharmaceuticalsGo to article: AlfatestLABGo to article: Alphial Company InsightGo to article: In DepthGo to article: Prodrugs and patents: Enhancing therapy adherence and reducing side effectsGo to article: Are PBMs to blame for high drug prices in the US?Go to article: Into the unknown: how quickly can vaccines be developed for Disease XGo to article: US negotiations for first round of drugs reveal $6bn in Medicare savings Go to article: Emerging microbiome market – unlocking new frontiers Go to article: Build or buy? Key considerations for in-house manufacturingGo to article: BiomeBank Company InsightGo to article: IMP Pharmaceutical ServicesGo to article: XylemGo to article: Sponsored SupplementsGo to article: Techniconsult Firenze Company InsightGo to article: PfanstiehlGo to article: Duoject Medical Systems Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: Next issue